Cargando…

Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution

INTRODUCTION: Coronavirus disease 2019 (COVID-19) is known to induce robust antibody response in most of the affected individuals. The objective of the study was to determine if we can harvest the test sensitivity and specificity of a commercial serologic immunoassay merely based on the frequency di...

Descripción completa

Detalles Bibliográficos
Autores principales: Habibzadeh, Farrokh, Habibzadeh, Parham, Yadollahie, Mahboobeh, Sajadi, Mohammad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Society of Medical Biochemistry and Laboratory Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195604/
https://www.ncbi.nlm.nih.gov/pubmed/35799990
http://dx.doi.org/10.11613/BM.2022.020705
_version_ 1784727001978896384
author Habibzadeh, Farrokh
Habibzadeh, Parham
Yadollahie, Mahboobeh
Sajadi, Mohammad M.
author_facet Habibzadeh, Farrokh
Habibzadeh, Parham
Yadollahie, Mahboobeh
Sajadi, Mohammad M.
author_sort Habibzadeh, Farrokh
collection PubMed
description INTRODUCTION: Coronavirus disease 2019 (COVID-19) is known to induce robust antibody response in most of the affected individuals. The objective of the study was to determine if we can harvest the test sensitivity and specificity of a commercial serologic immunoassay merely based on the frequency distribution of the SARS-CoV-2 immunoglobulin (Ig) G concentrations measured in a population-based seroprevalence study. MATERIALS AND METHODS: The current study was conducted on a subset of a previously published dataset from the canton of Geneva. Data were taken from two non-consecutive weeks (774 samples from May 4-9, and 658 from June 1-6, 2020). Assuming that the frequency distribution of the measured SARS-CoV-2 IgG is binormal (an educated guess), using a non-linear regression, we decomposed the distribution into its two Gaussian components. Based on the obtained regression coefficients, we calculated the prevalence of SARS-CoV-2 infection, the sensitivity and specificity, and the most appropriate cut-off value for the test. The obtained results were compared with those obtained from a validity study and a seroprevalence population-based study. RESULTS: The model could predict more than 90% of the variance observed in the SARS-CoV-2 IgG distribution. The results derived from our model were in good agreement with the results obtained from the seroprevalence and validity studies. Altogether 138 of 1432 people had SARS-CoV-2 IgG ≥ 0.90, the cut-off value which maximized the Youden’s index. This translates into a true prevalence of 7.0% (95% confidence interval 5.4% to 8.6%), which is in keeping with the estimated prevalence of 7.7% derived from our model. Our model can provide the true prevalence. CONCLUSIONS: Having an educated guess about the distribution of test results, the test performance indices can be derived with acceptable accuracy merely based on the test results frequency distribution without the need for conducting a validity study and comparing the test results against a gold-standard test.
format Online
Article
Text
id pubmed-9195604
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Croatian Society of Medical Biochemistry and Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-91956042022-07-06 Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution Habibzadeh, Farrokh Habibzadeh, Parham Yadollahie, Mahboobeh Sajadi, Mohammad M. Biochem Med (Zagreb) Original Articles INTRODUCTION: Coronavirus disease 2019 (COVID-19) is known to induce robust antibody response in most of the affected individuals. The objective of the study was to determine if we can harvest the test sensitivity and specificity of a commercial serologic immunoassay merely based on the frequency distribution of the SARS-CoV-2 immunoglobulin (Ig) G concentrations measured in a population-based seroprevalence study. MATERIALS AND METHODS: The current study was conducted on a subset of a previously published dataset from the canton of Geneva. Data were taken from two non-consecutive weeks (774 samples from May 4-9, and 658 from June 1-6, 2020). Assuming that the frequency distribution of the measured SARS-CoV-2 IgG is binormal (an educated guess), using a non-linear regression, we decomposed the distribution into its two Gaussian components. Based on the obtained regression coefficients, we calculated the prevalence of SARS-CoV-2 infection, the sensitivity and specificity, and the most appropriate cut-off value for the test. The obtained results were compared with those obtained from a validity study and a seroprevalence population-based study. RESULTS: The model could predict more than 90% of the variance observed in the SARS-CoV-2 IgG distribution. The results derived from our model were in good agreement with the results obtained from the seroprevalence and validity studies. Altogether 138 of 1432 people had SARS-CoV-2 IgG ≥ 0.90, the cut-off value which maximized the Youden’s index. This translates into a true prevalence of 7.0% (95% confidence interval 5.4% to 8.6%), which is in keeping with the estimated prevalence of 7.7% derived from our model. Our model can provide the true prevalence. CONCLUSIONS: Having an educated guess about the distribution of test results, the test performance indices can be derived with acceptable accuracy merely based on the test results frequency distribution without the need for conducting a validity study and comparing the test results against a gold-standard test. Croatian Society of Medical Biochemistry and Laboratory Medicine 2022-06-15 2022-06-15 /pmc/articles/PMC9195604/ /pubmed/35799990 http://dx.doi.org/10.11613/BM.2022.020705 Text en Croatian Society of Medical Biochemistry and Laboratory Medicine. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Habibzadeh, Farrokh
Habibzadeh, Parham
Yadollahie, Mahboobeh
Sajadi, Mohammad M.
Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution
title Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution
title_full Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution
title_fullStr Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution
title_full_unstemmed Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution
title_short Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution
title_sort determining the sars-cov-2 serological immunoassay test performance indices based on the test results frequency distribution
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195604/
https://www.ncbi.nlm.nih.gov/pubmed/35799990
http://dx.doi.org/10.11613/BM.2022.020705
work_keys_str_mv AT habibzadehfarrokh determiningthesarscov2serologicalimmunoassaytestperformanceindicesbasedonthetestresultsfrequencydistribution
AT habibzadehparham determiningthesarscov2serologicalimmunoassaytestperformanceindicesbasedonthetestresultsfrequencydistribution
AT yadollahiemahboobeh determiningthesarscov2serologicalimmunoassaytestperformanceindicesbasedonthetestresultsfrequencydistribution
AT sajadimohammadm determiningthesarscov2serologicalimmunoassaytestperformanceindicesbasedonthetestresultsfrequencydistribution